Welcome to our dedicated page for Integra Lifesciences Hldgs Cp news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra Lifesciences Hldgs Cp stock.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) is a global leader in medical technology, headquartered in Plainsboro, New Jersey. Established in 1989, Integra is dedicated to reducing uncertainty for surgeons, allowing them to focus on providing outstanding patient care. The company offers innovative solutions in various medical fields including orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery.
Integra's diverse portfolio includes products for regenerative therapy, extremity orthopedics, and neurosurgical applications. Their orthopedic product line features devices and implants for spine, foot and ankle, hand and wrist, shoulder and elbow, tendon and peripheral nerve protection and repair, and wound repair. The company is also a key player in the neurosurgery market, offering a broad range of implants, devices, instruments, and systems used in neurosurgery, neuromonitoring, neurotrauma, and critical care.
Integra operates through two main segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical segment generates the majority of the company's revenue, focusing on neurosurgical and surgical instrumentation. The Tissue Technologies segment covers regenerative and advanced wound care products.
With over 3,500 employees worldwide, Integra serves markets in Europe, the Asia-Pacific region, and other parts of the globe, although the bulk of its revenue comes from domestic sales. Recently, the company announced its second-quarter 2023 financial results, highlighting a total revenue of $381.3 million, a slight decline compared to the previous year, primarily due to a recall issue at their Boston manufacturing facility. Despite this, the company showed resilience with strong performances in certain product lines and updated their guidance for 2023 revenue and earnings per share.
Integra's recent acquisition of Acclarent, a leader in ENT procedures, for $275 million, showcases their ongoing commitment to expanding their product offerings and improving healthcare outcomes. This acquisition is expected to close by the second quarter of 2024 and will significantly bolster Integra's position in the ENT market.
Integra continues to develop and launch groundbreaking products such as the CereLink ICP Monitoring System for intracranial pressure monitoring and the MicroMatrix Flex, which addresses complex wound reconstruction needs. These innovations reflect Integra's dedication to advancing surgical, neurologic, and regenerative care standards.
For the latest updates and further information, visit www.integralife.com.
Campbell Soup Company (NYSE:CPB) announced the appointment of
Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced preliminary financial results for the fourth quarter and full-year 2022, revealing expected revenues of $397-$398 million for Q4, a 2% decrease reported but a 3% organic increase year-over-year. For the full year, revenues are projected at $1,557-$1,558 million, reflecting a 1% reported increase and 4% organic growth. Adjusted earnings per diluted share for both periods are expected to exceed prior guidance. The company also plans a $150 million share repurchase program in 2023 and will present at the J.P. Morgan Healthcare Conference on January 11.
Integra LifeSciences (NASDAQ: IART) announced that its CEO, Jan De Witte, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 7:30 PM ET. A live webcast will be accessible through Integra's investor relations website. The company, recognized for its regenerative tissue technologies and neurosurgical solutions, aims to support clinicians in delivering optimal patient care. Integra boasts a robust portfolio of high-quality brands.
Integra LifeSciences (NASDAQ:IART) has completed its acquisition of Surgical Innovation Associates (SIA). This strategic move aims to enhance Integra's position as a leader in implant-based breast reconstruction (IBBR) procedures, as stated by Robert T. Davis, Jr., Executive VP at Integra. The company emphasizes its commitment to improving patient outcomes through innovative technologies. Integra is known for its extensive portfolio in regenerative tissue technologies and neurosurgical solutions, promising a focus on high-quality patient care.
Integra LifeSciences (NASDAQ:IART) announced the acquisition of Surgical Innovation Associates (SIA) for $50 million, with potential additional payments totaling $90 million based on performance metrics. This strategic acquisition enhances Integra's product offerings in plastic and reconstructive surgery, particularly in breast reconstruction, addressing a growing market opportunity. The FDA is currently reviewing Integra's pre-market approval application for its existing SurgiMend product, and the transaction is expected to be dilutive to earnings in year one but accretive by year three.
Integra LifeSciences (Nasdaq: IART) has reached a definitive agreement to acquire Surgical Innovation Associates (SIA) for up to
Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported Q3 2022 revenues of $385 million, a decrease of 0.4% year-over-year, with a 3.5% increase on an organic basis. GAAP earnings per diluted share rose to $0.60, compared to $0.51 last year. The company raised its EPS outlook to $3.29-$3.33 and reaffirmed revenue guidance between $1,551-$1,563 million, indicating organic growth of 3.7%-4.5%. The TWC business was sold for $28.8 million, and cash flow from operations reached $68 million. Full-year guidance reflects adjustments due to foreign currency impacts.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) plans to release its third quarter 2022 financial results on October 26, 2022, before market opening. This will be followed by a conference call hosted by the management team at 8:30 a.m. ET. Investors can access the call by dialing 866-571-0905 with passcode 1121226# or through a live webcast on the company’s website. A replay will be available until November 7, 2022.
Integra LifeSciences (NASDAQ: IART) announced the appointment of Harvinder Singh as executive vice president and president of its international business. Singh brings over 20 years of experience from Abbott Laboratories, where he held various senior roles, including vice president of global commercial operations in the vascular sector. His expertise is expected to support Integra's growth strategy in international markets. Singh holds degrees in chemistry and biology from Punjab University and an MBA from the University of Indore, along with completing the Harvard Business School’s Advanced Management Program.
FAQ
What is the current stock price of Integra Lifesciences Hldgs Cp (IART)?
What is the market cap of Integra Lifesciences Hldgs Cp (IART)?
What does Integra LifeSciences Holdings Corp. specialize in?
Where is Integra LifeSciences headquartered?
What are the primary segments of Integra LifeSciences?
What recent acquisition was announced by Integra LifeSciences?
What are some of the key products offered by Integra LifeSciences?
How did Integra perform financially in the second quarter of 2023?
What is the purpose of Integra’s CereLink ICP Monitoring System?
How many employees does Integra LifeSciences have?
Which markets does Integra LifeSciences serve?
What is Integra’s strategy for growth in 2024?
